Avanos Medical, Inc.
Avanos Medical, Inc. (AVNS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
avns · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Avanos Medical, Inc. (AVNS) measures how much investors pay for each dollar of the company's trailing earnings. AVNS's current PE ratio of N/A is calculated by dividing its stock price of $25.05 by its TTM earnings per share of -$1.50.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2011 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 9 fiscal years · Front-end computedMinQ1 · 25%27.1x
MedianQ3 · 75%264.7x
Max
At N/A, AVNS's current P/E is lower than in 0% of its annual fiscal year readings over the past 9 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Avanos Medical, Inc.You AVNS | $1.2B | N/A | — | -$1.50 |
 Bicycle Therapeutics plc BCYC | $291M | N/A | — | -$3.16 |
 Bioventus Inc. BVS | $612M | 21.81x | +92.7% | $0.34 |
 CeriBell, Inc. CBLL | $692M | N/A | — | -$1.46 |
 ClearPoint Neuro, Inc. CLPT | $387M | N/A | — | -$0.90 |
 Cytek Biosciences, Inc. CTKB | $528M | N/A | — | -$0.52 |
 Community Health Systems, Inc. CYH | $386M | 0.82x | -92.7% | $3.80 |
Industry Average 2 peers with valid PE | — | 11.31x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.46 | — | |
2024-12-31 FY2024 | — | $-8.52 | — | |
2023-12-31 FY2023 | — | $-1.33 | — | |
2022-12-31 FY2022 | 25.13x | $1.08 | -90.5% | |
2021-12-31 FY2021 | 264.70x | $0.13 | — | |
2020-12-31 FY2020 | — | $-0.57 | — | |
2019-12-31 FY2019 | — | $-0.96 | — | |
2018-12-31 FY2018 | 36.77x | $1.22 | +35.7% | |
2017-12-31 FY2017 | 27.09x | $1.70 | -37.4% | |
2016-12-31 FY2016 | 43.30x | $0.85 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Avanos Medical, Inc. (AVNS) measures how much investors pay for each dollar of the company's trailing earnings. AVNS's current PE ratio of N/A is calculated by dividing its stock price of $25.05 by its TTM earnings per share of -$1.50.
Frequently asked questions
AVNS pe ratio · 6 questionsAVNS's current PE ratio is N/A as of 2026-06-08, based on a stock price of $25.05 and TTM EPS of -$1.50. Data sourced from Financial Modeling Prep via AVNS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Avanos Medical, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08